"Incomplete lupus" is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...
Medpage Today on MSN6d
Lupus Patients See More Vascular Risk, but It's ModifiableAtherosclerosis progression was more than twice as common in younger people with systemic lupus erythematosus (SLE) than in ...
“Incomplete lupus” is a term used to describe a person who has some symptoms of lupus but not enough to make the diagnosis ...
Belantamab mafodotin is under clinical development by GSK and currently in Phase I for Systemic Lupus Erythematosus.
The prevalence of fibromyalgia is higher among patients with SLE vs the general population, adding to an already significant ...
Patients with SLE have a higher prevalence of primary headaches vs those with RA or pSS, but similar percentages were found ...
A new study explored the potential of IncRNA CASC2 and miR-155 levels as non-invasive diagnostic biomarkers for systemic lupus erythematosus (SLE) and lupus nephritis (LN). Previous studies have found ...
A-319 is under clinical development by ITabMed and currently in Phase I for Systemic Lupus Erythematosus. According to GlobalData, Phase I drugs for Systemic Lupus Erythematosus have a 73% phase ...
Discover a study where results suggest that patients with cutaneous lupus erythematosus may benefit from increased vigilance ...
The increased risks for arterial thrombotic events (ATE), venous thromboembolism (VTE), and all-cause mortality known to be ...
to discuss on this Care Cues episode how to facilitate shared decision-making in patients with systemic lupus. Jennifer L. Barton, MD, MCR: Liana, we're talking about lupus today, which is a very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback